Stemline Therapeutics News Releases https://ir.stemline.com/ Stemline Therapeutics News Releases en Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-announces-presentation-elzonris NEW YORK , June 17, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics announced today that ELZONRIS (tagraxofusp) was the subject of preclinical data in Mon, 17 Jun 2019 07:30:00 -0400 Stemline Therapeutics News Releases 10656 Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp) Clinical Presentations at EHA Congress June 13-15 https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-announces-three-elzonris-tagraxofusp NEW YORK , June 13, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced that ELZONRIS™ (tagraxofusp) is the subject of three clinical Thu, 13 Jun 2019 07:30:00 -0400 Stemline Therapeutics News Releases 10651 Stemline Therapeutics Announces ASCO Presentation of ELZONRIS Phase 2 Clinical Data in CMML and MF; Provides Next Steps for CMML Program https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-announces-asco-presentation-elzonris-phase NEW YORK , June 03, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced that ELZONRIS™ (tagraxofusp) Phase 2 clinical data in chronic Mon, 03 Jun 2019 07:30:00 -0400 Stemline Therapeutics News Releases 10636 Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-announces-elzonris-clinical-data-0 NEW YORK , May 20, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp) clinical data in blastic plasmacytoid Mon, 20 May 2019 07:00:00 -0400 Stemline Therapeutics News Releases 10631 Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-announces-elzonris-clinical-data-selected NEW YORK , May 16, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp) clinical data in chronic myelomonocytic Thu, 16 May 2019 07:00:00 -0400 Stemline Therapeutics News Releases 10616 Stemline Therapeutics Reports First Quarter 2019 Financial Results https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-reports-first-quarter-2019-financial Net revenue for ELZONRIS was $5.05 million for the first quarter Conference call and live webcast scheduled for today at 8:00 AM ET NEW YORK , May 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and Fri, 10 May 2019 06:30:00 -0400 Stemline Therapeutics News Releases 10591 Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019 https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-host-conference-call-first-quarter-2019 NEW YORK , May 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the company will host a conference call and live webcast on Wed, 08 May 2019 07:00:00 -0400 Stemline Therapeutics News Releases 10576 Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-announces-new-england-journal-medicine NEW YORK , April 25, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the pivotal trial results of ELZONRIS™ (tagraxofusp), a Thu, 25 Apr 2019 07:00:00 -0400 Stemline Therapeutics News Releases 10551 Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-participate-panel-myeloid-tumors-31st NEW YORK , March 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that Ivan Bergstein , M.D., Stemline’s CEO, was selected to Mon, 18 Mar 2019 07:00:00 -0400 Stemline Therapeutics News Releases 10541 Stemline Therapeutics Reports Fourth Quarter 2018 Financial Results https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-reports-fourth-quarter-2018-financial NEW YORK , March 15, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today financial results for the quarter ended December 31, 2018 . Fri, 15 Mar 2019 16:01:00 -0400 Stemline Therapeutics News Releases 10506